Ocugen's banner

Ocugen

@Ocugen • 64,577 subscribers

Approaching healthcare innovation with ingenuity, passion and courage to create new solutions to difficult medical challenges. Guidelines: https://t.co/SYzUIr1zPD

Shorts

Ocugen announces U.S. FDA clearance of IND amendment to initiate OCU400 Phase 3 (liMeliGhT) Clinical Trial--the first gene therapy to enter Phase 3 with a broad retinitis pigmentosa indication. For more information, read the full press release here.

Ocugen announces U.S. FDA clearance of IND amendment to initiate OCU400 Phase 3 (liMeliGhT) Clinical Trial--the first gene therapy to enter Phase 3 with a broad retinitis pigmentosa indication. For more information, read the full press release here.

14,294 Aufrufe

Videos

Anya Rossi

sweetdream.ai

SweetDream.ai•Sponsored•Livecam

Watch Anya Live

Anya is streaming live right now! Join her private show and enjoy exclusive content.

Exclusive private shows

1.2k viewers online

Private Show

Join now for exclusive access

Free preview available • Premium content

Today, CEO Shankar Musunuri announced a major advancement for #OCU410 and #geographicatrophy: the first patient dosed in our global Phase 3 trial. We are one step closer to a potential one-time treatment for life and our target of 3 BLAs by 2028. 🔗 $OCGN

Today, CEO Shankar Musunuri announced a major advancement for #OCU410 and #geographicatrophy: the first patient dosed in our global Phase 3 trial. We are one step closer to a potential one-time treatment for life and our target of 3 BLAs by 2028. 🔗 $OCGN

11,455 Aufrufe • vor 1 Monat

Susan, an #OCU410ST participant, saw stabilization in her treated eye after #Stargardtdisease treatment, while the untreated eye declined. Now in Phase 2/3, OCU410ST could become the first approved therapy for Stargardt disease. Follow us for updates.

Susan, an #OCU410ST participant, saw stabilization in her treated eye after #Stargardtdisease treatment, while the untreated eye declined. Now in Phase 2/3, OCU410ST could become the first approved therapy for Stargardt disease. Follow us for updates.

11,298 Aufrufe • vor 6 Monaten

Today, CEO Shankar Musunuri shares encouraging 12-month Phase 2 results for #OCU410 in GA, showing impact on lesion growth and visual function. A one-time gene therapy approach with potential to shift the landscape and address unmet needs. Read more:

Today, CEO Shankar Musunuri shares encouraging 12-month Phase 2 results for #OCU410 in GA, showing impact on lesion growth and visual function. A one-time gene therapy approach with potential to shift the landscape and address unmet needs. Read more:

11,557 Aufrufe • vor 7 Monaten

We are now enrolling patients as young as 3 in our OCU410ST Phase 2/3 GARDian3 clinical trial for #Stargardtdisease. Phase 1 data shows 100% stabilization or improvement in treated eyes and 48.2% slower lesion growth. Learn more: clinical.request@ocugen.com #OCU410ST #Ocugen

We are now enrolling patients as young as 3 in our OCU410ST Phase 2/3 GARDian3 clinical trial for #Stargardtdisease. Phase 1 data shows 100% stabilization or improvement in treated eyes and 48.2% slower lesion growth. Learn more: [email protected] #OCU410ST #Ocugen

13,661 Aufrufe • vor 1 Jahr

31 years after her #retinitispigmentosa diagnosis, Nancy is experiencing change through treatment in the #OCU400 clinical trial. She reports better definition, improved light adaptation, and can read without a magnifier. Modifier gene therapy:

31 years after her #retinitispigmentosa diagnosis, Nancy is experiencing change through treatment in the #OCU400 clinical trial. She reports better definition, improved light adaptation, and can read without a magnifier. Modifier gene therapy:

10,267 Aufrufe • vor 9 Monaten

Keine weiteren Inhalte verfügbar